Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors

被引：19

作者：

Tettamanti, Sarah ^{[1
]}

Magnani, Chiara Francesca ^{[1
]}

Biondi, Andrea ^{[1
]}

Biagi, Ettore ^{[1
]}

机构：

[1] Univ Milano Bicocca, San Gerardo Hosp, Dept Pediat, Ctr Ric Matilde Tettamanti, I-20052 Monza, Italy

来源：

IMMUNOLOGY LETTERS | 2013年 / 155卷 / 1-2期

关键词：

Acute myeloid leukemia (AML); Monoclonal antibody (mAb); Chimeric antigen receptor (CAR); Cytokine-induced killer (CIK) cells; Immunotherapy; Gene therapy; INDUCED KILLER-CELLS; RECEPTOR-ALPHA CHAIN; GEMTUZUMAB-OZOGAMICIN; INDUCTION THERAPY; RANDOMIZED-TRIAL; EXPRESSION; ANTIGEN; RECOMMENDATIONS; MANAGEMENT; INFUSIONS;

D O I：

10.1016/j.imlet.2013.09.013

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In the context of acute myeloid leukemia (AML) treatment, the interface between chemotherapy and immunotherapy is at present getting closer as never before. Scientific research is oriented in overcoming the main limits of actual chemotherapeutic regimens against AML, which still accounts for a considerable number of relapsed or resistant forms. A lot of investments have been done in the use of monoclonal antibodies (mAbs) and recently gene-modified immune cells have been considered as an alternative approach whenever chemotherapy fails to eradicate the disease. In this sense, AML is a potential suitable target for immunotherapeutic approaches, due to overexpression of several tumor antigens. Here we describe the state of the art of mAbs and cellular therapies employing engineered immune effectors, developed against specific AML antigens, in a window embracing preclinical research and translational studies to the clinical setting. (C) 2013 Elsevier B.V. All rights reserved.

引用

页码：43 / 46

页数：4

共 41 条

[21] Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study [J].

Introna, Martino ;

Borleri, Gianmaria ;

Conti, Elena ;

Franceschetti, Marta ;

Barbui, Anna Maria ;

Broady, Raewyn ;

Dander, Erica ;

Gaipa, Giuseppe ;

D'Amico, Giovanna ;

Biagi, Ettore ;

Parma, Matteo ;

Pogliani, Enrico M. ;

Spinelli, Orietta ;

Baronciani, Donatella ;

Grassi, Anna ;

Golay, Josee ;

Barbui, Tiziano ;

Biondi, Andrea ;

Rambaldi, Alessandro .

HAEMATOLOGICA, 2007, 92 (07) :952-959

[22] A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results [J].

Introna, Martino ;

Algarotti, Alessandra ;

Mico, Caterina ;

Grassi, Anna ;

Pievani, Alice ;

Borleri, Gianmaria ;

Golay, Josee ;

Cavattoni, Irene ;

Cortelazzo, Sergio ;

Rambaldi, Alessandro .

BLOOD, 2011, 118 (21) :300-300

[23] Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells [J].

Jin, Liqing ;

Lee, Erwin M. ;

Ramshaw, Hayley S. ;

Busfield, Samantha J. ;

Peoppl, Armando G. ;

Wilkinson, Lucy ;

Guthridge, Mark A. ;

Thomas, Daniel ;

Barry, Emma F. ;

Boyd, Andrew ;

Gearing, David P. ;

Vairo, Gino ;

Lopez, Angel F. ;

Dick, John E. ;

Lock, Richard B. .

CELL STEM CELL, 2009, 5 (01) :31-42

[24] The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells [J].

Jordan, CT ;

Upchurch, D ;

Szilvassy, SJ ;

Guzman, ML ;

Howard, DS ;

Pettigrew, AL ;

Meyerrose, T ;

Rossi, R ;

Grimes, B ;

Rizzieri, DA ;

Luger, SM ;

Phillips, GL .

LEUKEMIA, 2000, 14 (10) :1777-1784

[25] Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group [J].

Kaspers, Gertjan J. L. ;

Zimmermann, Martin ;

Reinhardt, Dirk ;

Gibson, Brenda E. S. ;

Tamminga, Rienk Y. J. ;

Aleinikova, Olga ;

Armendariz, Hortensia ;

Dworzak, Michael ;

Ha, Shau-Yin ;

Hasle, Henrik ;

Hovi, Liisa ;

Maschan, Alexei ;

Bertrand, Yves ;

Leverger, Guy G. ;

Razzouk, Bassem I. ;

Rizzari, Carmelo ;

Smisek, Petr ;

Smith, Owen ;

Stark, Batia ;

Creutzig, Ursula .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) :599-607

[26] TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells [J].

Kikushige, Yoshikane ;

Shima, Takahiro ;

Takayanagi, Shin-ichiro ;

Urata, Shingo ;

Miyamoto, Toshihiro ;

Iwasaki, Hiromi ;

Takenaka, Katsuto ;

Teshima, Takanori ;

Tanaka, Toshiyuki ;

Inagaki, Yoshimasa ;

Akashi, Koichi .

CELL STEM CELL, 2010, 7 (06) :708-717

[27] Auger Electron Radioimmunotherapeutic Agent Specific for the CD123+/CD131- Phenotype of the Leukemia Stem Cell Population [J].

Leyton, Jeffrey Victor ;

Hu, Meiduo ;

Gao, Catherine ;

Turner, Patricia V. ;

Dick, John E. ;

Minden, Mark ;

Reilly, Raymond M. .

JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (09) :1465-1473

[28] Cytokine-Induced NK-Like T Cells: From Bench to Bedside [J].

Linn, Yeh Ching ;

Hui, Kam M. .

JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2010,

[29]

Maher John, 2012, ISRN Oncol, V2012, P278093, DOI 10.5402/2012/278093

[30] Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells [J].

Majeti, R. .

ONCOGENE, 2011, 30 (09) :1009-1019

← 1 2 3 4 5 →